NASDAQ:CGON CG Oncology Q2 2026 Earnings Report $72.55 -1.24 (-1.68%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$72.54 0.00 (-0.01%) As of 09/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CG Oncology EPS ResultsActual EPS-$0.90Consensus EPS -$0.66Beat/MissMissed by -$0.24One Year Ago EPSN/ACG Oncology Revenue ResultsActual Revenue$1.16 millionExpected Revenue$0.36 millionBeat/MissBeat by +$796.00 thousandYoY Revenue GrowthN/ACG Oncology Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time8:30AM ETUpcoming EarningsCG Oncology's Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CG Oncology Earnings HeadlinesCG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of "Moderate Buy" from Analysts4 hours ago | americanbankingnews.comCG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14 at 9:00 PM | seekingalpha.comWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax that year in exchange for potential tax-free qualified growth later. Key questions remain: how much to convert, where the tax payment comes from, and whether this years income leaves room. Roth IRAs also avoid lifetime required minimum distributions. A fiduciary financial advisor can help size a conversion around your specific tax situation and goals.September 16 at 1:00 AM | SmartAsset (Ad)Critical Survey: CG Oncology (NASDAQ:CGON) vs. HCW Biologics (NASDAQ:HCWB)September 8, 2026 | americanbankingnews.comCG Oncology to Present at Upcoming Investor Conferences in SeptemberSeptember 2, 2026 | globenewswire.comKuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmAugust 19, 2026 | prnewswire.comSee More CG Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email. Email Address About CG OncologyCG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biotechnology company focused on developing therapies for bladder cancer. The company’s research is centered on treatments designed to stimulate the immune system and target tumors directly, with an emphasis on non-muscle-invasive bladder cancer (NMIBC). Its lead investigational product, cretostimogene grenadenorep, also known as CG0070, is an intravesical oncolytic adenovirus intended for administration directly into the bladder. The therapy is designed to selectively replicate in cancer cells, promote tumor-cell destruction and stimulate an immune response through the production of granulocyte-macrophage colony-stimulating factor (GM-CSF). CG Oncology has evaluated the candidate in clinical studies involving patients with NMIBC, including disease that has not responded adequately to Bacillus Calmette-Guérin (BCG) treatment. CG Oncology is headquartered in Irvine, California, and its activities are primarily focused on advancing its bladder-cancer pipeline through clinical development and regulatory evaluation. The company’s executive leadership includes Arthur Kuan, who serves as chief executive officer. As a development-stage biotechnology company, CG Oncology’s principal product candidate remains investigational and is subject to clinical and regulatory review.View CG Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks RiskyCould Dave & Buster’s Capitulation Signal the Bottom Is Finally In?Navan's Strong Quarter Meets an AI Spending Reality Check3 Defense Stocks Riding the High-Energy Laser BoomLightPath’s Defense Pivot Could Send Shares Higher3 Dividend Kings to Buy While They’re Still Beaten DownAnalysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
